Concordia, Ono Pharmaceutical deal

Concordia granted Ono exclusive rights to develop and commercialize salirasib in Japan. The Ras antagonist has completed a Phase IIa trial for non-small cell lung cancer (NSCLC) and a Phase I/II tria...